Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 134, Issue 1, 2007, Pages 110-114

  Borgfeldt, Christer ^a   Iosif, Constantin ^a   Måsbäck, Anna ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Fertility sparing therapy; Human; Ovarian neoplasm; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM; FEMALE; FERTILITY; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; OUTCOME ASSESSMENT; OVARY; OVARY CANCER; OVARY TUMOR; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 34548213186     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2006.05.037     Document Type: Article

References (34)

1. Cancer incidence in Sweden. Official Statistics of Sweden-Health and Diseases. Cancer incidence in Sweden 2003. Stockholm, Sweden: The National Board of Health and Welfare, Centre for Epidemiology 2004;10:1-116.
2. Pecorelli S, Benedet J, Beller U, Creasman W, Heintz A, Pettersson F. FIGO Annual Report on the Results of Treatment in Gynaecological Cancer. Oxford: Isis Medical Media 2001;6:1-184.
3. Morris R.T., Gershenson D.M., Silva E.G., Follen M., Morris M., and Wharton J.T. Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol 95 4 (2000) 541-547
4. Morice P., Camatte S., El Hassan J., Pautier P., Duvillard P., and Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 75 1 (2001) 92-96
5. Schilder J.M., Thompson A.M., DePriest P.D., et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 23 5 (2002) 1-7
6. Morice P., Wicart-Poque F., Rey A., et al. Results of conservative treatment in epithelial ovarian carcinoma. Cancer 53 1, Suppl. 1 (2001) 2412-2418
7. Zanetta G., Chiari S., Rota S., et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol 8 1 (1996) 1030-1035
8. Zanetta G., Rota S., Lissoni A., Meni A., Brancatelli G., and Buda A. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol 19 4 (2001) 63-66
9. Kaern J., Trope C.G., Kristensen G.B., Abeler V.M., and Pettersen E.O. DNA ploidy: the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 3 5 (1993) 349-358
10. Trope C.G., Kristensen G., and Makar A. Surgery for borderline tumor of the ovary. Semin Surg Oncol 19 1 (2000) 69-75
11. Cass I., Li A.J., Runowicz C.D., et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 322 15 (1990) 56-61
12. Morice P., Joulie F., Camatte S., et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 197 2 (2003) 198-205
13. Silverberg S.G., Bell D.A., Kurman R.J., et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol 35 8 (2004) 910-917
14. Ronnett B.M., Kajdacsy-Balla A., Gilks C.B., et al. Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol 47 3 (2005) 949-960
15. Bell D.A., Longacre T.A., Prat J., et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 35 8 (2004) 934-948
16. Sherman M.E., Mink P.J., Curtis R., et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100 5 (2004) 1045-1052
17. Jaffe E., Harris N., Stein H., and Vardiman J. WHO classification of tumours-pathology and genetics of tumours of the breast and female genital organs (2003), IARC Press, Lyon
18. Young R.C., Walton L.A., Ellenberg S.S., et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 25 1 (2003) 1021-1027
19. Colombo N., Guthrie D., Chiari S., et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95 2 (2003) 125-132
20. Le T., Krepart G.V., Lotocki R.J., and Heywood M.S. Clinically apparent early stage invasive epithelial ovarian carcinoma: should all be treated similarly?. Gynecol Oncol 67 2 (1997) 252-254
21. Trimbos J.B., Vergote I., Bolis G., et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95 2 (2003) 113-125
22. Zanetta G., Rota S., Chiari S., Bonazzi C., Bratina G., and Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 19 1 (2001) 2658-2664
23. Williams T.J., and Dockerty M.B. Status of the contralateral ovary in encapsulated low grade malignant tumors of the ovary. Surg Gynecol Obstet 143 5 (1976) 763-766
24. Bostwick D.G., Tazelaar H.D., Ballon S.C., Hendrickson M.R., and Kempson R.L. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 95 4 (2000) 2052-2065
25. Morice P., Leblanc E., Rey A., et al. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Societe Francaise d'Oncologie Gynecologique). Hum Reprod 20 5 (2005) 1379-1385
26. Kristensen G.B., Kildal W., Abeler V.M., et al. Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Ann Oncol 361 9375 (2003) 1494-1500
27. Salazar H., Godwin A.K., Daly M.B., et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 88 24 (1996) 1810-1820 [See comments]
28. Kaur T.B., Shen T., Gaughan J., et al. Premalignant lesions in the contralateral ovary of women with unilateral ovarian carcinoma. Gynecol Oncol 93 1 (2004) 69-77
29. Stirling D., Evans D.G., Pichert G., et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics system. J Clin Oncol 23 24 (2005) 5588-5596
30. Olivier R.I., Lubsen-Brandsma M.A., Verhoef S., and van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 100 1 (2006) 20-26
31. Jacobs I.J., and Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3 4 (2004) 355-366
32. Ahmed F.Y., Wiltshaw E., A'Hern R.P., et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 14 11 (1996) 2968-2975
33. Vergote I., De Brabanter J., Fyles A., et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357 9251 (2001) 176-182
34. Rao G.G., Skinner E.N., Gehrig P.A., Duska L.R., Miller D.S., and Schorge J.O. Fertility-sparing surgery for ovarian low malignant potential tumors. Gynecol Oncol 98 2 (2005) 263-266